Previous close | 0.0500 |
Open | 0.0200 |
Bid | 0.0000 |
Ask | 0.1300 |
Strike | 160.00 |
Expiry date | 2024-01-19 |
Day's range | 0.0200 - 0.0500 |
Contract range | N/A |
Volume | |
Open interest | 183 |
(Bloomberg) -- The global market for novel weight-loss drugs like Novo Nordisk A/S’s Ozempic and Wegovy is poised to reach $100 billion by 2035 as patients start to understand the efficacy of the medications.Most Read from BloombergChina’s Ultra-Rich Gen Zs Flock Home as Global Tensions RiseAI Fantasy Fades as Wall Street Reels From Real-World Rate JumpRaw Meat-Eating Liver King And Other Health Influencers Face Mounting LawsuitsTinder Offers $500-a-Month Subscription to Its Most Active UsersWhy
Based on analysts' projections, you might think the pharmaceutical giant isn't worth investing in right now.
Eli Lilly, Toyota Motor, Accenture, The Walt Disney and CVS Health are part of the Zacks top Analyst Blog.